Iwermac-A Tablet contains a combination of Ivermectin (6 mg) and Albendazole (400 mg), which are antiparasitic agents used to treat a variety of parasitic infections. Ivermectin acts by binding to glutamate-gated chloride channels in the nerve and muscle cells of parasites, leading to paralysis and death of the parasite. Albendazole works by inhibiting microtubule synthesis in parasitic worms, disrupting their glucose uptake and depleting their energy stores, ultimately causing their death. This combination is effective against a broad spectrum of helminthic infections, including strongyloidiasis, onchocerciasis, filariasis, ascariasis, trichuriasis, hookworm infections, and neurocysticercosis. Iwermac-A is typically prescribed for single or multiple dose regimens depending on the type and severity of infection. It is important to use this medication under medical supervision, as dosage adjustments may be necessary for patients with liver impairment or other comorbidities. Common side effects may include dizziness, nausea, abdominal pain, and headache, but these are generally mild and transient. Patients should inform their healthcare provider of any allergies or concurrent medications to avoid potential drug interactions. Iwermac-A Tablet offers an effective therapeutic option for managing parasitic infestations with a convenient combination formulation.